Currently in the US, pembrolizumab is the only one of these agents approved by the US Food and Drug Administration (FDA) for first-line monotherapy of metastatic NSCLC (for tumors negative for epidermal growth factor receptor/anaplastic lymphoma kinase [EGFR/ALK] genomic alterations). Here, ALK is linked to non-small cell lung carcinoma.